Biopharmaceuticals · global
Hepatitis B “Functional Cure” Nears Phase 3 Threshold as GSK Nucleic Acid Drug Reaches Regulatory Gate
Bepirovirsen kept some chronic hepatitis B patients in a state of hepatitis B surface antigen loss in two late-stage trials, opening a narrow path in a treatment landscape long limited to viral suppression; but response rates of just over 10% to about 20% also show this is not the final answer.
The most difficult aspect of chronic hepatitis B is not only whether the virus can be suppressed, but that patients often need to take medication for years, or even for life, while still struggling to truly shed markers of infection. Bepirovirsen, an antisense oligonucleotide drug developed by GSK and Ionis, has recently produced signals of a “functional cure” in two international Phase 3 studies, bringing a field long short of breakthroughs closer to a clinical turning point.
According to reporting by Associated Press, two late-stage trials showed that about one-fifth of chronic hepatitis B patients who received bepirovirsen plus standard therapy achieved a functional cure; the placebo group did not show a comparable response. The functional cure referred to here usually means loss of hepatitis B surface antigen and sustained viral control, rather than complete clearance of viral genes from inside liver cells.
The significance of the results is that they target the final stretch that current nucleoside or nucleotide analogue therapies have struggled to cross. Standard drugs can effectively suppress viral replication and reduce the risk of cirrhosis and liver cancer, but they rarely lead to loss of hepatitis B surface antigen. Bepirovirsen, through an antisense oligonucleotide mechanism, attempts to interfere with virus-related RNA, reduce production of viral proteins, and give the immune system a chance to regain control.
The Times, reporting on the same set of Phase 3 data, said GSK described the results as statistically significant and clinically meaningful, and views bepirovirsen as one of several important future launch products. The drug was originally licensed by Ionis to GSK; the report also noted that GSK had previously expected bepirovirsen, if approved, could have peak annual sales of more than £2 billion. These commercial expectations indicate the scale of the drugmaker’s bet, but they do not mean the scope of clinical use has already been determined.
Regulatory review will be the next gate. Associated Press reported that bepirovirsen has entered review procedures in the United States, Europe, Japan, and China, with a U.S. FDA decision expected in October 2026. The Times also mentioned that the drug had received accelerated review-related arrangements because of unmet medical need in chronic hepatitis B. However, the final label, eligible population, treatment duration, and safety monitoring requirements will remain unclear until regulators complete their assessments.
Clinically, several questions still cannot be obscured by the four words “functional cure.” First, a response rate of about one-fifth means most patients did not reach the same outcome. Which viral states, immune backgrounds, or prior treatment histories can predict benefit will affect future drug selection. Second, antisense oligonucleotide drugs typically require attention to injection-related reactions, liver indicators, and long-term safety follow-up; the summaries currently public are not enough to fully interpret the risk profile.
**Background Context**
A large number of people worldwide with chronic hepatitis B still face risks of cirrhosis and liver cancer, and treatment goals are also shifting from simply suppressing the virus toward whether some patients can maintain control after stopping medication. If approved, bepirovirsen could become one of the first drugs to push this goal into mainstream clinical decision-making; but it is more likely to open an era of stratified treatment than to rewrite all hepatitis B care at once.